Order Article Reprints

Takada H, Osawa L, Komiyama Y, Kato R, Nakakuki N, Muraoka M, Suzuki Y, Tatsumi A, Sato M, Takahashi E, et al. Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma. Reports. 2021; 4(3):25. https://doi.org/10.3390/reports4030025

Takada, Hitomi, Leona Osawa, Yasuyuki Komiyama, Ryoh Kato, Natsuko Nakakuki, Masaru Muraoka, Yuichiro Suzuki, Akihisa Tatsumi, Mitsuaki Sato, Ei Takahashi, and et al. 2021. "Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma" Reports 4, no. 3: 25. https://doi.org/10.3390/reports4030025

Takada, H., Osawa, L., Komiyama, Y., Kato, R., Nakakuki, N., Muraoka, M., Suzuki, Y., Tatsumi, A., Sato, M., Takahashi, E., Takano, S., Fukasawa, M., Yamaguchi, T., Inoue, T., Maekawa, S., & Enomoto, N. (2021). Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma. Reports, 4(3), 25. https://doi.org/10.3390/reports4030025